Evidence-based pharmacotherapy of panic disorder

This paper reviews the literature on the pharmacotherapy of panic disorder, in order to address the questions (1) what is the first-line pharmacotherapy of choice for panic disorder?, (2) for how long should maintenance pharmacotherapy be continued, and (3) what is the optimal approach to the treatm...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of neuropsychopharmacology 2005-09, Vol.8 (3), p.473-482
Main Authors: Bakker, Abraham, van Balkom, Anton J. L. M., Stein, Dan J.
Format: Article
Language:English
Subjects:
Antidepressive Agents - classification
Antidepressive Agents - therapeutic use
Evidence-Based Medicine
Humans
MEDLINE
Meta-Analysis as Topic
Panic Disorder - drug therapy
Panic Disorder - epidemiology
Special Series
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This paper reviews the literature on the pharmacotherapy of panic disorder, in order to address the questions (1) what is the first-line pharmacotherapy of choice for panic disorder?, (2) for how long should maintenance pharmacotherapy be continued, and (3) what is the optimal approach to the treatment-refractory patient with panic disorder. A MEDLINE search (1966–2003) was undertaken to collate randomized controlled trials of pharmacotherapy in panic disorder. A review of the evidence indicates that SSRIs are currently the first line agent of choice in panic disorder, and that pharmacotherapy should be continued for at least 1 year. There has been relatively little research on the pharmacotherapy of treatment-refractory panic disorder, and this area requires future attention.
ISSN:1461-1457
1469-5111
DOI:10.1017/S1461145705005201